Cargando…
Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines
INTRODUCTION: Dengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9–45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prio...
Autores principales: | Dai, Yu-Ching, Sy, Ava Kristy, Jiz, Mario, Tsai, Jih-Jin, Bato, Joan, Quinoñes, Mary Ann, Reyes, Mary Anne Joy, Wang, Wei-Kung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405517/ https://www.ncbi.nlm.nih.gov/pubmed/37554332 http://dx.doi.org/10.3389/fimmu.2023.1202055 |
Ejemplares similares
-
Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines
por: Flasche, Stefan, et al.
Publicado: (2019) -
Dengvaxia: the world’s first vaccine for prevention of secondary dengue
por: Tully, Danielle, et al.
Publicado: (2021) -
Genetic Diversity and Dispersal of DENGUE Virus among Three Main Island Groups of the Philippines during 2015–2017
por: Sy, Ava Kristy, et al.
Publicado: (2023) -
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
por: Galula, Jedhan Ucat, et al.
Publicado: (2019) -
Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations
por: Godói, Isabella P., et al.
Publicado: (2017)